Newsletter Tool

Today’s Big News

Nov 4, 2024

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist

Viking's oral obesity med sails ahead, posting 6.8% weight loss for highest dose in phase 1

AstraZeneca talks up potential for obesity combo treatments, insists it's ‘playing to win’ in crowded field

BigHat unveils next-gen ADC designed with Lonza’s Synaffix as lead program

The Column Group's biotech taps Surrozen for lung disease research pact

Israeli computational biology company turns to Google Cloud for AI model-building power

In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals

Featured

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist

By James Waldron

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Viking's oral obesity med sails ahead, posting 6.8% weight loss for highest dose in phase 1

By James Waldron

Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed data from its phase 1 trial that suggest its dual agonist of GLP-1 and GIP can hold its own in a crowded field.

AstraZeneca talks up potential for obesity combo treatments, insists it's ‘playing to win’ in crowded field

By James Waldron

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

Overcoming Barriers to Generative AI in Life Sciences R&D

BigHat unveils next-gen ADC designed with Lonza’s Synaffix as lead program

By Gabrielle Masson

BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline.

The Column Group's biotech taps Surrozen for lung disease research pact

By Darren Incorvaia

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover antibodies for idiopathic pulmonary fibrosis.

Israeli computational biology company turns to Google Cloud for AI model-building power

By Darren Incorvaia

Israeli computational biology company Evogene is looking to the clouds to secure the computational power it needs to develop an AI model for designing small molecules.

In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals

By Angus Liu

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against competitors.

Doctors, facing another pay cut in 2025, call for permanent Medicare payment reform

By Heather Landi

The Centers for Medicare and Medicaid Services is moving forward with a 2.9% cut to physician payments in 2025 despite protest from major industry groups.

Fierce podcasts

Don’t miss an episode

Drug pricing and the 2024 presidential election

This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

Closing the menopause care gap

The pulse of the medtech industry

Resources

Whitepaper

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Intensified Biomanufacturing

Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game!

Sponsored by: Syngene International Ltd.

Whitepaper

Is That Heart Attack Really an Adverse Event?

Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results.

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific